CoChat

Blood-based extracellular matrix biomarkers are correlated with clinical outcome after PD-1 inhibition in patients with metastatic melanoma

Open access

The DOI matches its Crossref record; 35 of the 37 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Immune checkpoint inhibitors that target the programmed cell death protein 1 (PD-1) receptor induce a response in only a subgroup of patients with metastatic melanoma. Previous research suggests that transforming growth factor beta signaling and a collagen-rich peritumoral stroma (tumor fibrosis), may negatively interfere with the interaction between T cells and tumor cells and thereby contribute to resistance mechanisms by immune-exclusion, while increased tumor infiltration of M1-like macrophages enhances T cell activity. Hence, the current study aimed to assess the relationship between blood-based markers of collagen or vimentin turnover (reflecting M1 macrophage activity) and clinical outcome in patients with metastatic melanoma after PD-1 inhibition. METHODS: Patients with metastatic melanoma who were treated with anti-PD-1 monotherapy between May 2016 and March 2019 were included in a prospective observational study. N-terminal pro-peptide of type III collagen (PRO-C3) cross-linked N-terminal pro-peptides of type III collagen (PC3X), matrix metalloprotease (MMP)-degraded type III (C3M) and type IV collagen (C4M), granzyme B-degraded type IV collagen and citrullinated and MMP-degraded vimentin (VICM) were measured with immunoassays in serum before (n=107), and 6 weeks after the first administration of immunotherapy (n=94). The association between biomarker levels and overall survival (OS) or progression-free survival (PFS) was assessed. RESULTS: Multivariate Cox regression analysis identified high baseline PRO-C3 (Q4) and PC3X (Q4) as independent variables of worse PFS (PRO-C3: HR=1.81, 95% CI=1.06 to 3.10, p=0.030 and PC3X: HR=1.86, 95% CI=1.09 to 3.18, p=0.023). High baseline PRO-C3 was also independently related to worse OS (HR=2.08, 95% CI=1.06 to 4.09, p=0.035), whereas a high C3M/PRO-C3 ratio was related to improved OS (HR=0.42, 95% CI=0.20 to 0.90, p=0.025). An increase in VICM (p<0.0001; in 56% of the patients) was observed after 6 weeks of treatment, and an increase in VICM was independently associated with improved OS (HR=0.28, 95% CI=0.10 to 0.77, p=0.014). CONCLUSIONS: Blood-based biomarkers reflecting excessive type III collagen turnover were associated with worse OS and PFS after PD-1 inhibition in metastatic melanoma. Moreover, an increase in VICM levels after 6 weeks of treatment was associated with improved OS. These findings suggest that type III collagen and vimentin turnover contribute to resistance/response mechanisms of PD-1 inhibitors and hold promise of assessing extracellular matrix-derived and stroma-derived components to predict immunotherapy response.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/jitc-2020-001193

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Association of extracellular matrix (ECM) biomarkers measured at baseline and progression-free survival (PFS). Kaplan-Meier plots demonstrating the association of ECM biomarkers with PFS for patients with metastatic melanoma. (A) PRO-C3, (B) PC3X, (C) C4G, (D) C3M, (E) C4M and (F) VICM were dichotomized into quartiles (Q4, representing the highest levels of the biomarker). P values are based on the log-rank test. C3M, C4M, matrix metalloprotease (MMP)-degraded type III and IV collagen; C4G, granzyme B-degraded type IV collagen; PC3X, cross-linked N-terminal pro-peptide of type III collagen; PRO-C3, N-terminal pro-peptide of type III collagen; VICM, citrullinated and MMP-degraded vimentin.
Figure 1 Association of extracellular matrix (ECM) biomarkers measured at baseline and progression-free survival (PFS). Kaplan-Meier plots demonstrating the association of ECM biomarkers with PFS for patients with metastatic melanoma. (A) PRO-C3, (B) PC3X, (C) C4G, (D) C3M, (E) C4M and (F) VICM were dichotomized into quartiles (Q4, representing the highest levels of the biomarker). P values are based on the log-rank test. C3M, C4M, matrix metalloprotease (MMP)-degraded type III and IV collagen; C4G, granzyme B-degraded type IV collagen; PC3X, cross-linked N-terminal pro-peptide of type III collagen; PRO-C3, N-terminal pro-peptide of type III collagen; VICM, citrullinated and MMP-degraded vimentin.CC BY-NC · PubMed Central
Figure 2 Association of extracellular matrix (ECM) biomarkers measured at baseline and overall survival (OS). Kaplan-Meier plots demonstrating the association of ECM biomarkers with OS for patients with metastatic melanoma. (A) PRO-C3, (B) PC3X, (C) C4G, (D) C3M, (E) C4M and (F) VICM were dichotomized into quartiles (Q4, representing the highest levels of the biomarker). P values are based on the log-rank test. C3M, C4M, matrix metalloprotease (MMP)-degraded type III and IV collagen; C4G, granzyme B-degraded type IV collagen; PC3X, cross-linked N-terminal pro-peptide of type III collagen; PRO-C3, N-terminal pro-peptide of type III collagen; VICM, citrullinated and MMP-degraded vimentin.
Figure 2 Association of extracellular matrix (ECM) biomarkers measured at baseline and overall survival (OS). Kaplan-Meier plots demonstrating the association of ECM biomarkers with OS for patients with metastatic melanoma. (A) PRO-C3, (B) PC3X, (C) C4G, (D) C3M, (E) C4M and (F) VICM were dichotomized into quartiles (Q4, representing the highest levels of the biomarker). P values are based on the log-rank test. C3M, C4M, matrix metalloprotease (MMP)-degraded type III and IV collagen; C4G, granzyme B-degraded type IV collagen; PC3X, cross-linked N-terminal pro-peptide of type III collagen; PRO-C3, N-terminal pro-peptide of type III collagen; VICM, citrullinated and MMP-degraded vimentin.CC BY-NC · PubMed Central
Figure 3 A high C3M/PRO-C3 ratio at baseline associate with good survival outcomes. Kaplan-Meier plots demonstrating the association of the C3M/PRO-C3 ratio with progression-free survival (PFS) (A) and overall survival (OS) (B) for patients with metastatic melanoma. Patients were divided based on a C3M/PRO-C3 ratio >1 or <1 and a log-rank test was used to determine differences between survival curves. C3M, matrix metalloprotease (MMP)-degraded type III collagen; PRO-C3, N-terminal pro-peptide of type III collagen.
Figure 3 A high C3M/PRO-C3 ratio at baseline associate with good survival outcomes. Kaplan-Meier plots demonstrating the association of the C3M/PRO-C3 ratio with progression-free survival (PFS) (A) and overall survival (OS) (B) for patients with metastatic melanoma. Patients were divided based on a C3M/PRO-C3 ratio >1 or <1 and a log-rank test was used to determine differences between survival curves. C3M, matrix metalloprotease (MMP)-degraded type III collagen; PRO-C3, N-terminal pro-peptide of type III collagen.CC BY-NC · PubMed Central
Figure 4 Increase in VICM after anti-programmed cell death protein 1 (anti-PD-1) treatment associates with progression-free survival (PFS) and overall survival (OS). Kaplan-Meier plots demonstrating the association of change in PRO-C3 (A, D), PC3X (B, E) and VICM (C, F) with PFS and OS 6 weeks after start of anti-PD-1 immune checkpoint inhibitor (ICI) therapy after stratification of patients based on an increase of >20% from baseline vs <20% increase. P values are based on the log-rank test. PC3X, cross-linked N-terminal pro-peptide of type III collagen; PRO-C3, N-terminal pro-peptide of type III collagen; VICM, citrullinated and MMP-degraded vimentin.
Figure 4 Increase in VICM after anti-programmed cell death protein 1 (anti-PD-1) treatment associates with progression-free survival (PFS) and overall survival (OS). Kaplan-Meier plots demonstrating the association of change in PRO-C3 (A, D), PC3X (B, E) and VICM (C, F) with PFS and OS 6 weeks after start of anti-PD-1 immune checkpoint inhibitor (ICI) therapy after stratification of patients based on an increase of >20% from baseline vs <20% increase. P values are based on the log-rank test. PC3X, cross-linked N-terminal pro-peptide of type III collagen; PRO-C3, N-terminal pro-peptide of type III collagen; VICM, citrullinated and MMP-degraded vimentin.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 35 references

Cited by

See all 49

Metadata

Authors
Hurkmans, D. P., Jensen, C., Koolen, S. L. W., Aerts, J., Karsdal, M. A., Mathijssen, R. H. J., & Willumsen, N.
Affiliations
  • Erasmus MC (NL)
  • Nordic Bioscience (Denmark) (DK)
  • Erasmus MC Cancer Institute (NL)
Corresponding author
Hurkmans, Daan P
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2020-10
Volume
8
Issue
2
Pages
e001193
ISSN
2051-1426 (ISSN-L)
OpenAlex
W3093845837
Cited by
49
References
37
Citations by year
2026: 7 · 2025: 8 · 2024: 7 · 2023: 9 · 2022: 10 · 2021: 7 · 2020: 1
FWCI
2.44
Type
journal article
Language
en
Open access
Locations
  • Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, cc-by-nc)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, cc-by-nc)
  • RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Erasmus Medisch Centrum
  • Danish Research Foundation
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Keywords
metastatic melanoma, anti-PD-1 therapy, immune checkpoint inhibitors, type III collagen, type IV collagen, vimentin, M1 macrophages, tumor fibrosis, immune exclusion, treatment response prediction, overall survival, progression-free survival, serum biomarkers, T cell infiltration, TGF-beta signaling
MeSH terms
Aged, Extracellular Matrix, Female, Humans, Male, Melanoma, Middle Aged, Biomarkers, Tumor, Treatment Outcome, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Blood-based extracellular matrix biomarkers are correlated with clinical outcome after PD-1 inhibition in patients with metastatic melanoma. https://app.cochat.ai/papers/10.1136/jitc-2020-001193
The paper
Hurkmans, D. P., Jensen, C., Koolen, S. L. W., Aerts, J., Karsdal, M. A., Mathijssen, R. H. J., & Willumsen, N. (2020). Blood-based extracellular matrix biomarkers are correlated with clinical outcome after PD-1 inhibition in patients with metastatic melanoma. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2020-001193

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.